Home
/ Xenikos

Xenikos

Xenikos

Total Funding

$37 M

Xenikos Summary

Company summary

Overview: Xenikos is a clinical-stage biopharmaceutical company. It develops immunotherapies based on the action of toxin-conjugated antibodies for patients suffering immune diseases, or rejection after transplantation.

Type: Private

Status: Active

Founded: 2012

HQ: Nijmegen, NL | view all locations

Website: https://www.xenikos.com

Cybersecurity rating

Sectors

Key people

Ypke van Oosterhout, Founder and Chief Executive Officer, Director
Douglas E. Williams, Chairman of the Board, Non-Executive Director
Maarten Frijlink, Chief Operating Officer
Jake Simson, Non-Executive Director

and 4 others

LocationsView all

1 location detected

Nijmegen, GE HQ
Netherlands
Wilhelminasingel 14

Competitors and similar companies

Compare competitors

News

Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jun 28, 2022

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Jun 27, 2022

Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer

Sep 22, 2021

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

Sep 8, 2021

Blogs

Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Jul 19, 2021